To the full analysis
Pfizer stock: growth
PFEPfizer reported $62.58B in revenue for fiscal 2025, down 1.6% on the prior year, up 8.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
1.4%
per year from 2006 to 2025, per share 2.7%
Earnings (Annual rate)
−4.7%
per year from 2006 to 2025, per share −0.6%
Free cash flow (Annual rate)
−2.8%
per year from 2006 to 2025, per share −1.5%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 8.5% | 2.5% | 1.4% |
| Revenue per share | 8.0% | 3.4% | 2.7% |
| Earnings | −3.2% | 1.1% | −4.7% |
| Earnings per share | −3.8% | 1.9% | −0.6% |
| Free cash flow | −4.8% | −3.5% | −2.8% |
| Free cash flow per share | −5.2% | −2.7% | −1.5% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $48.37B | $19.34B | $15.54B |
| 2007 | $48.42B | $8.14B | $11.47B |
| 2008 | $48.3B | $8.1B | $16.54B |
| 2009 | $50.01B | $8.64B | $15.38B |
| 2010 | $65.17B | $8.26B | $9.94B |
| 2011 | $61.04B | $10.01B | $18.58B |
| 2012 | $54.66B | $14.57B | $15.73B |
| 2013 | $51.58B | $22B | $16.3B |
| 2014 | $49.61B | $9.14B | $15.3B |
| 2015 | $48.85B | $6.96B | $13.02B |
| 2016 | $52.82B | $7.22B | $13.9B |
| 2017 | $52.55B | $21.31B | $14.25B |
| 2018 | $40.83B | $11.15B | $13.63B |
| 2019 | $40.91B | $16.03B | $9.99B |
| 2020 | $41.65B | $9.16B | $11.61B |
| 2021 | $81.29B | $21.98B | $29.87B |
| 2022 | $101.18B | $31.37B | $26.03B |
| 2023 | $59.55B | $2.12B | $4.79B |
| 2024 | $63.63B | $8.03B | $9.84B |
| 2025 | $62.58B | $7.77B | $9.08B |
Revenue by region
Where Pfizer Inc. generates its revenue.
- United States59%
- Developed Rest Of World26%
- Emerging Markets15%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| United States | $38.69B | $37.08B | 59.2% |
| Developed Rest Of World | $16.06B | $16.19B | 25.9% |
| Emerging Markets | $8.88B | $9.31B | 14.9% |
| Total revenue | $63.63B | $62.58B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 Nov 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.